HUTCHMED (China) Ltd (HCM): Cash & Equivalents
$71.33M
As of 2025-12-31
-38.9%
3-year compound annual growth
-21.3%
5-year compound annual growth
+8.4%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $71.33M | -53.7% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $153.96M | -45.7% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $283.59M | -9.5% | 2025-03-19, Balance as of period end |
| 2022-12-31 | $313.28M | -17.0% | 2024-02-28, Balance as of period end |
| 2021-12-31 | $377.54M | +60.2% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $235.63M | +94.5% | 2022-03-03, Balance as of period end |
| 2019-12-31 | $121.16M | +40.8% | 2021-03-04, Balance as of period end |
| 2018-12-31 | $86.04M | +0.9% | 2020-03-03, Balance as of period end |
| 2017-12-31 | $85.27M | +7.3% | 2019-03-11, Balance as of period end |
| 2016-12-31 | $79.43M | +148.7% | 2018-03-12, Balance as of period end |
| 2015-12-31 | $31.94M | -18.0% | 2018-03-12, Balance as of period end |
| 2014-12-31 | $38.95M | n/a | 2017-03-13, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $71.33M | -53.7% |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $93.68M | -30.9% |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $296.68M | +33.3% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $570.12M | -16.3% |
| Insmed Inc (INSM) | 2025-12-31 | $510.44M | -8.0% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $364.41M | -14.6% |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $93.03M | +58.9% |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $79.15M | -56.0% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $93.89M | +10.9% |
Compare HCM, ORGO, MIRM, BBIO side by side · Screen every company in Pharmaceutical Preparations ↗